Featured Research

from universities, journals, and other organizations

One cell type may quash tumor vaccines

Date:
April 28, 2014
Source:
Thomas Jefferson University
Summary:
Many cancer vaccines fail because the immune cells that would destroy the tumor are actively suppressed, researchers believe. Now they have found that a single cell type may be to blame for the suppression, paving the way to better cancer vaccine design. "The conventional wisdom is that the body knocks out all of the cells that can mount an immune response to the cancer," says the study's first author. "In fact, our work shows that it's only one cell type that is affected. But that cell, the T-helper cell, acts as the lynchpin."

Most cancer vaccines have not lived up to their promise in clinical trials. The reason, many researchers suspect, is that the immune cells that would help the body destroy the tumor -- even those reactions boosted by cancer vaccines -- are actively suppressed. Now, researchers at Thomas Jefferson University have found that a single cell type is actively suppressed in several experimental cancer vaccines, paving the way toward methods to break suppression and improve the effectiveness of cancer vaccines. The work was published this week online in the European Journal of Immunology.

"The conventional wisdom is that the body knocks out all of the cells that can mount an immune response to the cancer," says first author Adam Snook, PhD, a Research Instructor at Thomas Jefferson University. "In fact, our work shows that it's only one cell type that is affected. But that cell, the T-helper cell, acts as the lynchpin."

Cancer vaccines are designed to boost the body's natural defenses against cancer. They work by training the immune system to recognize and attack specific tumor peptides, which are a kind of identification tag for tumors. These peptide "tags" help the immune system find and attack cancer cells. There are three types of cells that can "see" and react to these tags: T-helper cells, cytotoxic T cells, and B cells, and researchers thought that all three were trained, or tolerized, to ignore the tags on cancer cells.

Dr. Snook and colleagues tested which cell was involved by inoculating mice with a cancer vaccine they developed for colorectal cancer using a tumor peptide called guanylyl cyclase C (GUCY2C). Normally, GUCY2C-vaccinated mice would not produce much of an immune response, from either T cell type or B cells. However, when the researchers boosted the GUCY2C vaccine by linking it to another peptide called S1 that efficiently activates T-helper cells, they were able to see a vigorous activation of cytotoxic T cells and B cells directed at GUCY2C.

In fact, the GUCY2C vaccine-S1 combo improved the survival time of mice with cancer by months compared to only days with GUCY2C vaccine alone. In fact, many mice were cured of their disease.

When Dr. Snook tested two other cancer peptides, one for breast cancer (Her2) and one for melanoma (Trp2), he saw similar results, suggesting that selective inactivation of T helper cells occurs for peptides found in many cancer types. "The results make a lot of sense," says Dr. Snook. "T-helper cells, as their name suggests, provide help to both cytotoxic T cells and to B cells. The entire peptide-specific immune response can be taken out by tolerizing this one cell type."

In addition, T-helper cells are also essential for creating immunological memory. Boosting T-helper cell activation also protected mice from challenge with cancer months after the initial vaccination, increasing their survival and decreasing tumor number.

The next step is to test whether a T helper peptide-linked GUCY2C vaccine could help fight colorectal cancer in humans. Dr. Snook and colleagues are currently enrolling patients in a clinical trial aimed at reducing the rate of cancer recurrence in patients who had their primary tumors removed.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Adam E. Snook, Michael S. Magee, Stephanie Schulz, Scott A. Waldman. Selective antigen-specific CD4 T-cell, but not CD8 T- or B-cell, tolerance corrupts cancer immunotherapy. European Journal of Immunology, 2014; DOI: 10.1002/eji.201444539

Cite This Page:

Thomas Jefferson University. "One cell type may quash tumor vaccines." ScienceDaily. ScienceDaily, 28 April 2014. <www.sciencedaily.com/releases/2014/04/140428133737.htm>.
Thomas Jefferson University. (2014, April 28). One cell type may quash tumor vaccines. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2014/04/140428133737.htm
Thomas Jefferson University. "One cell type may quash tumor vaccines." ScienceDaily. www.sciencedaily.com/releases/2014/04/140428133737.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins